reason report
recap lower outlook set stage market growth
bottom line remain market perform view
compani still inadequ posit growth biolog
like lose share emerg standard biomolecular
analysi close tie competitor product
adopt new product includ bioaccord remain year away
view share trade lower today major revenu miss
compani deliv flat y/i revenu growth earn
growth view instrument lead indic growth
declin instrument sale bode well futur growth
recur revenu consum servic contract also lag
behind peer china declin ta busi declin
given challeng find hard see recoveri
growth could potenti acceler stop buyback
start invest aggress growth transform acquisit
take step stop share loss core account renew product
focu regain posit lead lc-m compani
still priorit share repurchas aggress invest
growth attract acquisit spent share
repurchas quarter expect repurchas anoth
share quarter vs pursu aggress invest
growth alloc capit toward attract acquisit could
help expand adjac market expect repurchas
share object increas leverag net-debt/
base check bioaccord like take number year
gain adopt biomolecular qa/qc lab launch
bioaccord believ current posit bioaccord
development stage biomolecul system ideal
regul qa/qc market howev qa/qc lab director gener
amen chang thu see bioaccord like take
year gain meaning traction spec bla nda
base check could take even longer get adopt
given end-market user open major chang
plan launch high resolut cyclic ion mobil mass spec
amercian societi mass spectrometri asm june confer
believ could benefit
lower guid reflect market growth ahead
lower guid dramat full year suggest
like grow market growth rate peer deliv
high singl digit doubl digit growth china contrast declin
china back new regul consolid gener
net debt total capit
price-to-earnings lt ep growth
life scienc tool diagnost
year price history/av daili volume mil
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
compani inform svb leerink llc research
revenu mm ep present ex-amort one-tim charg
drug due lower guid lower ep
estim estim
given share repo peer group valuat model arriv
pt
rate water share market perform price target view
market perform given earlier sale forc realign continu impact lc-m
sale year believ steadi rise complex biomolecul bring
emerg standard includ mam multi attribut monitor alreadi becom
standard close attach orbitrap platform vs mass spec
pose threat uptak instrument longer term attempt address via
launch bioaccord system product still remain earli take multipl year
gain traction highli regul pharma qa/qc emerg standard rapidli gain
traction drug development head toward stronghold qa/qc despit
lc compani core custom expect mass spec util
ramp higher regul qa/qc industry-lead empow cd softwar
also like see increas competit see empow cd chrom data system
key recur instrument consum sale biopharma qa/qc
like face increas competit chromeleon agil open lab
come time key oper technic leadership transit mani
take retir believ face number headwind multipl front near
term longer term valuat reflect competit headwind compani
increasingli face view share buy-back market cap
strong continu provid support stock near-to-medium term
pt reflect ev/ebitda multipl line ev/
ebitda lst multipl share current trade line tool averag
believ would warrant higher multipl sale rep reach full product
help drive lc-m growth biopharma market still believ offer premium
product potenti return growth sale rep new mass spec product
challeng launch bioaccord address meet biotherapeut need market
deriv price target appli averag ev/ebitda multipl compris
primari risk price target includ
could acceler stock repurchas help drive stock higher one could also
envis biopharma uptick drive equival revenu growth across competitor
uptick biopharmaceut fund could pose risk know market remain
fda approv process directli impact biopharma biotech compani
could continu favor older method continu domin biopharma drug
sale could continu acceler result acceler spend current
level revenu deriv biopharma uptick spend
biopharma like increas revenu
acceler global budget research could caus upsid risk forecast expand
budget govern academ fund could result higher revenu rel
estim signific academ exposur revenu ww
nih exposur less revenu pickup academ spend could
headwind rate estim increas global budget could result shift
focu strategi growth could increas oper risk
emerg market pose signific upsid risk view despit signific growth
china far acceler uptak product could impact view sudden
macroeconom chang lead increas fund fund could impact water
posit china repres compani revenu chang regul
lead easier oper china foreign compani like benefit well given
posit market
high attach rate integr part busi model despit entri high
resolut mass spec lc could continu remain demand drive sale higher
estim could continu maintain legaci high attach rate lc
system due requir technolog competit chang market
fda regul remain paramount affect adopt rate clinic diagnost
tool clinic diagnost remain major growth area futur chang
regul restrict use mass spectromet clinic diagnost laboratori could
also improv compani prospect restrict could affect growth adopt rate certain
tool regul would also increas cost complianc test purpos
fx
fx
buy-back
rest
good sold
interest expens incom
sg sale
 sale
oper expens sale
compani report svb leerink estim
